JP2017506630A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506630A5
JP2017506630A5 JP2016550779A JP2016550779A JP2017506630A5 JP 2017506630 A5 JP2017506630 A5 JP 2017506630A5 JP 2016550779 A JP2016550779 A JP 2016550779A JP 2016550779 A JP2016550779 A JP 2016550779A JP 2017506630 A5 JP2017506630 A5 JP 2017506630A5
Authority
JP
Japan
Prior art keywords
complex
seq
amino acid
group
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016550779A
Other languages
English (en)
Japanese (ja)
Other versions
JP6619743B2 (ja
JP2017506630A (ja
Filing date
Publication date
Priority claimed from GB201402006A external-priority patent/GB201402006D0/en
Application filed filed Critical
Publication of JP2017506630A publication Critical patent/JP2017506630A/ja
Publication of JP2017506630A5 publication Critical patent/JP2017506630A5/ja
Application granted granted Critical
Publication of JP6619743B2 publication Critical patent/JP6619743B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016550779A 2014-02-06 2015-02-04 抗体−薬物複合体及び免疫毒素 Active JP6619743B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201402006A GB201402006D0 (en) 2014-02-06 2014-02-06 Antibody-drug conjugates and immunotoxins
GB1402006.9 2014-02-06
PCT/EP2015/052341 WO2015118030A2 (en) 2014-02-06 2015-02-04 Antibody-drug conjugates and immunotoxins

Publications (3)

Publication Number Publication Date
JP2017506630A JP2017506630A (ja) 2017-03-09
JP2017506630A5 true JP2017506630A5 (enExample) 2018-03-15
JP6619743B2 JP6619743B2 (ja) 2019-12-11

Family

ID=50390517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550779A Active JP6619743B2 (ja) 2014-02-06 2015-02-04 抗体−薬物複合体及び免疫毒素

Country Status (16)

Country Link
US (2) US10137202B2 (enExample)
EP (1) EP3102244B1 (enExample)
JP (1) JP6619743B2 (enExample)
KR (1) KR102342935B1 (enExample)
CN (1) CN105979971B (enExample)
AU (1) AU2015215015B2 (enExample)
CA (1) CA2937455C (enExample)
DK (1) DK3102244T3 (enExample)
ES (1) ES2788864T3 (enExample)
GB (1) GB201402006D0 (enExample)
HU (1) HUE049291T2 (enExample)
MX (1) MX375383B (enExample)
PL (1) PL3102244T3 (enExample)
PT (1) PT3102244T (enExample)
SI (1) SI3102244T1 (enExample)
WO (1) WO2015118030A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402006D0 (en) * 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
JP2018523712A (ja) * 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のvdasの使用
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
SG11202011139YA (en) * 2018-05-16 2020-12-30 Dragonfly Therapeutics Inc Protein binding nkg2d, cd16 and a fibroblast activation protein
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
CN118955620A (zh) 2019-07-08 2024-11-15 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CN111499685A (zh) * 2020-03-30 2020-08-07 联宁(苏州)生物制药有限公司 具有马来酰亚胺连接头的抗体偶联药物中间体及其合成方法
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
KR102799318B1 (ko) 2020-08-11 2025-04-23 주식회사 카나프테라퓨틱스 Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4274835A1 (en) 2021-01-07 2023-11-15 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CN119072325A (zh) 2022-02-11 2024-12-03 治纳辅医药科技有限公司 包含含有il-12和抗fap抗体的融合蛋白以及抗癌剂的用于癌症治疗的药物组合物
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
KR20230162310A (ko) 2022-05-20 2023-11-28 주식회사 카나프테라퓨틱스 Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
EP4311557A1 (en) 2022-07-26 2024-01-31 Oncomatryx Biopharma, S.L. Fap-targeted antibody-drug conjugates
AU2024400671A1 (en) 2023-12-15 2026-07-16 Kyowa Kirin Co., Ltd. Divalent bet decomposition agent and targeting molecule-drug complex
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
EP4616869A1 (en) 2024-03-15 2025-09-17 Oncomatryx Biopharma, S.L. Fap targeted antibody-drug conjugates
EP4684806A1 (en) 2024-07-22 2026-01-28 Oncomatryx Biopharma, S.L. Fap-targeted antibody-drug conjugates

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938505B1 (en) 1996-05-31 2002-03-06 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
CA2401252A1 (en) * 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
US20020099180A1 (en) 2000-03-17 2002-07-25 Klaus Pfizenmaier Human FAP-alpha-specific antibodies
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
DE102005036542A1 (de) * 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
EP2148886B1 (en) * 2007-05-10 2014-02-19 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
CN102339094A (zh) * 2010-07-21 2012-02-01 英业达股份有限公司 服务器
PE20171512A1 (es) * 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
CN104640572B (zh) * 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物,偶联方法,及其用途
PL2872157T3 (pl) * 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
GB201402006D0 (en) * 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins

Similar Documents

Publication Publication Date Title
JP2017506234A5 (enExample)
JP2017518040A5 (enExample)
JP2020079252A5 (enExample)
IL317587A (en) Antibody against SIRPalpha
JP2020502271A5 (enExample)
JP2018505177A5 (enExample)
JP2019535254A5 (ja) 抗pd−l1抗体および変異型
JP2017528476A5 (enExample)
JP2017530722A5 (enExample)
JP2013510868A5 (enExample)
JP2020503001A5 (enExample)
JP2020500538A5 (enExample)
JP2017500028A5 (enExample)
JP2010535713A5 (enExample)
JP2018070648A5 (enExample)
JP2015509947A5 (enExample)
JPWO2021177438A5 (enExample)
JP2016523810A5 (enExample)
JP2017519759A5 (enExample)
JP2017510661A5 (enExample)
JP2016538318A5 (enExample)
JP2017534256A5 (enExample)
JP2011505146A5 (enExample)
JP2017514461A5 (enExample)
JP2008500815A5 (enExample)